

Combination and integration to redirect NK cells for cancer immunotherapy

Citation for published version (APA):

Gong, Y. (2021). *Combination and integration to redirect NK cells for cancer immunotherapy*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20211130yg>

Document status and date:

Published: 01/01/2021

DOI:

[10.26481/dis.20211130yg](https://doi.org/10.26481/dis.20211130yg)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Propositions

- 1. Fully humanized anti-MUC1 antibodies, especially after Fc fragment defucosylation, are promising therapeutic candidates for NK cell-mediated cancer immunotherapy (this thesis).**
- 2. Rosuvastatin plus GGPP importantly enhances VSV-G lentivirus transduction efficiency without a negative impact on NK cell cytotoxicity (this thesis).**
- 3. NK cells equipped with a chimeric antigen receptor (CAR) are emerging as powerful effector cells for cancer therapy (this thesis).**
- 4. CRISPR/Cas9-mediated NKG2A deletion in NK cells promotes anti-tumor responses and may help them to exert their function in an inhibitory tumor microenvironment (this thesis).**
- 5. CAR-NK cells may be a safer, more efficient and more cost-effective alternative to CAR-T cells (Impact Paragraph).**
- 6. NK cells have the potential to act both in driving inflammation and in restricting adaptive immune responses that may otherwise lead to excessive inflammation or even autoimmunity (Zitti B, et al. 2018).**
- 7. Clinical cancer immunotherapy application can only be performed if experimental and fundamental research is properly funded.**
- 8. Inflammation is at the base of most human disease.**
- 9. Less is more (Ludwig Mies van der Rohe).**
- 10. 海内存知己，天涯若比邻—王勃 (Long distance separates no bosom friends.—WangBo).**
- 11. 吾生也有涯，而知也无涯—《庄子》 (There is no destination for the pursuit of knowledge in our finite lifetime - ZhuangZi).**